New Kids on the Block: IL-23 Inhibitors in IBD Management

Jacob Jones; Jeevin Sandhu; Kara Jones; David Dulaney; Anish Patel

doi:10.1007/s11894-025-01020-3

New Kids on the Block: IL-23 Inhibitors in IBD Management

Jacob Jones, Jeevin Sandhu, Kara Jones, David Dulaney, Anish Patel^*

^*Corresponding author for this work

Gastroenterology

Research output: Contribution to journal › Review article › peer-review

Abstract

Purpose of the Review: Review the efficacy and safety of IL2319 inhibitors in the management of IBD. Recent Findings: Risankizumab, mirikizumab, and guselkumab have been found to be efficacious and safe in the management of IBD. Summary: IL23p19 inhibitors have been found to be successful in the management of IBD. The new class of biologics adds to the growing armamentarium of medical options and could additionally prove beneficial as dual therapy.

Original language	English
Article number	68
Journal	Current Gastroenterology Reports
Volume	27
Issue number	1
DOIs	https://doi.org/10.1007/s11894-025-01020-3
State	Published - Dec 2025

Keywords

Biologic therapy
Crohn’s disease
IL23
Inflammatory bowel disease
P19 inhibitors
Ulcerative colitis

Access to Document

10.1007/s11894-025-01020-3

Cite this

@article{26c43266370644c4a88e4d7a7c28c534,

title = "New Kids on the Block: IL-23 Inhibitors in IBD Management",

abstract = "Purpose of the Review: Review the efficacy and safety of IL2319 inhibitors in the management of IBD. Recent Findings: Risankizumab, mirikizumab, and guselkumab have been found to be efficacious and safe in the management of IBD. Summary: IL23p19 inhibitors have been found to be successful in the management of IBD. The new class of biologics adds to the growing armamentarium of medical options and could additionally prove beneficial as dual therapy.",

keywords = "Biologic therapy, Crohn{\textquoteright}s disease, IL23, Inflammatory bowel disease, P19 inhibitors, Ulcerative colitis",

author = "Jacob Jones and Jeevin Sandhu and Kara Jones and David Dulaney and Anish Patel",

note = "Publisher Copyright: {\textcopyright} This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025.",

year = "2025",

month = dec,

doi = "10.1007/s11894-025-01020-3",

language = "English",

volume = "27",

journal = "Current Gastroenterology Reports",

issn = "1522-8037",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - New Kids on the Block

T2 - IL-23 Inhibitors in IBD Management

AU - Jones, Jacob

AU - Sandhu, Jeevin

AU - Jones, Kara

AU - Dulaney, David

AU - Patel, Anish

N1 - Publisher Copyright: © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025.

PY - 2025/12

Y1 - 2025/12

N2 - Purpose of the Review: Review the efficacy and safety of IL2319 inhibitors in the management of IBD. Recent Findings: Risankizumab, mirikizumab, and guselkumab have been found to be efficacious and safe in the management of IBD. Summary: IL23p19 inhibitors have been found to be successful in the management of IBD. The new class of biologics adds to the growing armamentarium of medical options and could additionally prove beneficial as dual therapy.

AB - Purpose of the Review: Review the efficacy and safety of IL2319 inhibitors in the management of IBD. Recent Findings: Risankizumab, mirikizumab, and guselkumab have been found to be efficacious and safe in the management of IBD. Summary: IL23p19 inhibitors have been found to be successful in the management of IBD. The new class of biologics adds to the growing armamentarium of medical options and could additionally prove beneficial as dual therapy.

KW - Biologic therapy

KW - Crohn’s disease

KW - IL23

KW - Inflammatory bowel disease

KW - P19 inhibitors

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=105019527901&partnerID=8YFLogxK

U2 - 10.1007/s11894-025-01020-3

DO - 10.1007/s11894-025-01020-3

M3 - Review article

C2 - 41123748

AN - SCOPUS:105019527901

SN - 1522-8037

VL - 27

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

IS - 1

M1 - 68

ER -